XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Details (Tables)

Condensed Consolidated Financial Statements Details (Tables)

3 Months Ended

Mar. 31, 2023

Condensed Consolidated Financial Statements Detail

Schedule of cost, accumulated amortization, and net carrying value of intangible assets

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of March 31, 2023 (in thousands):


			Accumulated		Net Carrying
	Cost		Amortization		Value
As of March 31, 2023
Ebopiprant IP (Note 4)	$	15,247	$	322	$	14,925
Total intangible assets	$	15,247	$	322	$	14,925

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands):


			Accumulated		Net Carrying
	Cost		Amortization		Value
As of December 31, 2022
Ebopiprant IP (Note 4)	$	15,247	$	97	$	15,150
Total intangible assets	$	15,247	$	97	$	15,150

Schedule of projected amortization expense for next five years

The remaining life of the intangible assets is 16.7 years. The following table presents the projected amortization expense for the next five years (in thousands):


	Intangible Asset
	Amortization

2023 (excluding three months ended March 31, 2023)	$	673
2024		897
2025		897
2026		897
2027		897
Total	$	4,261

Schedule of accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Arbitration settlement costs (Note 9)		4,132		—
Accrued payroll, severance and retention costs		1,087		1,449
Accrued legal and accounting fees		504		867
Accrued incentive compensation		304		562
Other accrued liabilities		100		40
Total	$	6,127	$	2,918

Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):


	Three Months Ended March 31,
	2023		2022
Numerator
Net loss	$	(9,813)	$	(2,280)
Less: Series A accumulated dividends		(530)		(530)
Less: Series B accumulated dividends		(838)		(838)
Net loss attributable to common stockholders, basic and diluted	$	(11,181)		(3,648)

Denominator
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders		11,460		11,330
Basic and diluted net loss per share attributable to common stockholders	$	(0.98)	$	(0.32)

Schedule of outstanding securities considered anti-dilutive

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):


	Three Months Ended March 31,
	2023	2022
Convertible preferred stock	5,003	5,003
Common stock options	1,548	697
Warrants for common stock	6	6
Total	6,557	5,706